

Trickett Wendler Right To Try (RTT) Act

First introduced in May 2016, the Trickett Wendler Right To Try (RTT) Act was re-introduced January 2017 by Sen Ron Johnson (R-Wis), chairman of the Senate Homeland Security and Governmental Affairs Committee. Intended to ensure terminally ill patients, their doctors, and pharmaceutical manufacturers are allowed to administer investigational treatments where no alternative treatment exists, it gives patients and doctors the freedom to try investigational treatments that have passed Phase 1 of the FDA's approval process, if they have exhausted all other treatment options.

Proponents argue that current government regulations wrongfully restrict access to potentially life-saving treatments and that patients have the right to determine what risks they are willing to undertake to save their own lives.

Interested in Learning More?

Hear both sides of the Right To Try debate and more at the **Pre-Approval Access Programs** this **September 25-27th** in **Philadelphia!**

HIGHLIGHTED SESSION

PANEL DISCUSSION: Explore How the New Trump Administration Affects the Future of Pre-approval
Tuesday September 26th, 2017

[Download Our Agenda](#)

The Opposition Opinion

However, the Right to Try Movement is not without controversy. In fact, a [2016 study](#) conducted by NYU School of Medicine Working Group on Compassionate Use and Pre-Approval Access (CUPA) found that:

- There are no substantiated cases of patients receiving experimental products because of a right by try law as companies are still under no legal obligation to grant access to experimental drugs
- When companies are willing to grant requests, the FDA actually approves 99+% of "compassionate use" requests
- The average turn around time for the FDA's expanded access program is 1 day or less for emergency requests; 4 days for non-emergency requests and the FDA form can be completed in under one hour.
- The FDA very rarely penalizes a drug company if its product causes an adverse event during pre-approval use -only .2% over the past 4 decades



Naomi Lopez Bauman
Director of Healthcare Policy
Goldwater Institute



Alison Bateman- House
Research Assistant Professor,
Division of Medical Ethics
NYU